- Global Pharma News & Resources

Blood Clotting Factors Market Size Estimation, Future Growth Insights, Share Analysis, Key Profile, Dynamics and Business Overview By 2026

Global Blood Clotting Factors Market

Blood clotting factors are proteins or enzymes that control bleeding. Blood clotting or blood coagulation is a process in which the blood gets converted into solid clots during the breakdown of blood vessels. Clotting can prevent death from bleeding and moreover, restrict the entry of bacteria and viruses into the body. Deficiency of the blood clotting factors can cause various blood clotting diseases, such as haemophilia and von willebrand disease (VWD). According to the Centre for Disease Control and Prevention (CDC), around 20,000 males were reported to be suffering from Haemophilia in the U.S. in 2017.

Get FREE Sample PDF Including COVID-19 Impact Analysis:

Approval of novel drugs in key regional markets, such as North America and Europe, is expected to boost the global blood clotting factors market development

In November 2017, the U.S. FDA approved Hemlibra (Emicizumab-kxwh) developed by Roche AG, for the treatment of Haemophilia A patient with inhibitors. This was the first approval by FDA in about 20 years to treat people with hemophilia A with inhibitors. Moreover, the FDA approved Adynovate of Shire Plc for the treatment of hemophilia A patients. The drug has also been approved for use in surgical setting for both category of patients, adult and pediatric. Furthermore, in January 2018, the drug (Adynovate) was granted marketing authorization in the European Union (EU). In the EU, the drug got approval for adults and adolescents suffering from Hemophilia A. These approvals provided an alternate treatment option for patients suffering from hemophilia. Introduction of these drugs into the market is said to have fueled the growth of the blood clotting factors market in the recent past.

Get Discount For Buyers UPTO 25% OFF On Any Research Report
Apply Promo Code “CHRISTMAS2020” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @

Global Blood Clotting Factors Market Taxonomy

By Product Type

  • Factor VII
  • Factor VIII
  • Factor IX
  • Factor X
  • Factor XIII
  • Von Willebrand Factor
  • Anti-Inhibitor Coagulant Complex
  • Others

By Application

  • Haemophilia
    • Haemophilia A
    • Haemophilia B
  • Von willebrand disease (VWD)
  • Surgery
  • Other bleeding disorders

By Technology

  • Plasma-derived
  • Recombinant

By Distribution channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Geography

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa

North America is expected to hold a dominant position in the global blood clotting factors market

Haemophilia is a rare disorder affecting very small fraction of population across the globe. Pharmaceutical companies invest less amount on development of such drugs due to low return on investment. However, FDA has recognized this fact and has formulated favorable policy to motivate companies to invest in this area. Orphan Drug Act that applies to company operating in this area provides three special incentives i.e. 7 years exclusivity period, tax credit and waiver of prescription drug user fees. Due to such policy, the company has invested in rare disease research which has led to development of products such as Hemlibra (Emicizumab-kxwh), Adynovate and Others. Furthermore, increasing awareness regarding rare disease in developed economies such as U.S. and Canada has resulted in high number of patients receiving treatment. Owing to the abovementioned factors, North America has led the global market in terms of market share and is expected to retain its position over the forecast period. However, Asia Pacific is expected to witness robust market growth due to the improved ratio of patients suffering from diseases and patients receiving treatments. Availability of generic products, at much lower price compared to branded product, in the market is expected to fuel growth of the Asia Pacific blood clotting factors market.

To get a detailed table of content (ToC), please click –

Significant Market Players

The key contenders operating in the global blood clotting factors market include Shire Plc, Baxter International Inc., Grifols International SA, Roche AG, Bayer AG, Pfizer Inc., Novo Nordisk A/S, Octapharma AG, Biogen Idec, and Kedrion S.P.A.

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website –


Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 08-Dec-2020